| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2027 ( Subtotal = -$307,401 ) |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K01AG078411 | Baboon model of chemotherapy-related cognitive impairment and accelerated aging | 000 | 5 | NIH | 10/28/2026 | -$28,374 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21AG103389 | Modeling age-dependent HSP90 decline and genome instability in mammals | 000 | 1 | NIH | 10/30/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122052 | Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells | 000 | 5 | NIH | 11/10/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA283514 | Examining the Role of Nono Pathway on the Innate Immunity Against Oncolytic Adenoviruses | 000 | 2 | NIH | 10/26/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122143 | Analyzing the Endothelial Cell-Expressed Prion Gene Prnd in Vascular Development | 000 | 5 | NIH | 11/10/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA303720 | Topical Therapy for Cutaneous Precancerous Lesions: a Digitally-enabled Randomized Controlled Trial of Fluorouracil compared with Fluorouracil/Calcipotriene | 000 | 1 | NIH | 11/9/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21ES039048 | Identifying PFAS-Induced Disruption of Placental Imprinting and Neurodevelopment Through Multi-Omic Negative Control Calibration | 000 | 1 | NIH | 10/19/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P30CA016672 | Cancer Center Support Grant | 000 | 50 | NIH | 10/14/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL178867 | Dissect the consequences of telomere stress on hematopoietic stem cells | 000 | 1 | NIH | 10/23/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61AG102807 | Development of a Nonhuman Primate Infrastructure for Interdisciplinary Research on Perimenopause and Aging | 000 | 1 | NIH | 11/3/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 2 | NIH | 10/14/2026 | $0 |
| | 2027 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA286745 | Mechanisms of CDH1-inactivated advanced gastric adenocarcinoma tumorigenesis | 000 | 2 | NIH | 10/14/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R13CA306203 | Cancer Neuroscience: Crossing Disciplines to Revolutionize Cancer Treatment | 000 | 1 | NIH | 10/20/2026 | -$12 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P30CA016672 | Cancer Center Support Grant | 001 | 49 | NIH | 11/4/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35CA263815 | Biology and Function of Exosomes in Cancer | 000 | 4 | NIH | 10/20/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA295902 | Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort | 000 | 1 | NIH | 11/10/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA292908 | Lymphedema Prevention Through Immediate Lymphatic Reconstruction | 000 | 2 | NIH | 11/6/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA285599 | Role of disparities and aging biomarkers in accelerated cardiac aging among adolescent and young adult cancer survivors | 001 | 2 | NIH | 11/3/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA285599 | Role of disparities and aging biomarkers in accelerated cardiac aging among adolescent and young adult cancer survivors | 002 | 2 | NIH | 11/5/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA285599 | Role of disparities and aging biomarkers in accelerated cardiac aging among adolescent and young adult cancer survivors | 000 | 2 | NIH | 11/2/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA293336 | A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer | 000 | 2 | NIH | 10/28/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA287287 | Maintenance of genome stability in 3D | 000 | 2 | NIH | 11/2/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R50CA265307 | Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC) | 000 | 5 | NIH | 11/6/2026 | -$1,260 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA101642 | Training of Academic Gynecologic Oncologists | 000 | 20 | NIH | 11/3/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA262557 | Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture | 000 | 6 | NIH | 11/2/2026 | $0 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA273661 | A novel uterine leiomyosarcoma mouse model for therapeutic development | 000 | 2 | NIH | 10/20/2026 | -$4,452 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA247307 | Improving Health Utilization and Quality of Life in Head and Neck Cancer Patients Undergoing Chemoradiation and their Family Caregivers | 000 | 6 | NIH | 10/30/2026 | -$12 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA247307 | Improving Health Utilization and Quality of Life in Head and Neck Cancer Patients Undergoing Chemoradiation and their Family Caregivers | 001 | 6 | NIH | 11/6/2026 | -$1 |
| | 2027 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA290034 | Interrogating the Role of Bacterial Methyl-modifying Enzymes in Pathoadaptation and Host Epigenetic Interference in Cancer | 000 | 2 | NIH | 10/30/2026 | $0 |
| | 2027 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA235673 | A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma | 000 | 6 | NIH | 11/6/2026 | -$11,797 |
| | 2027 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DK091310 | MicroRNA In Diabetic Nephropathy | 000 | 15 | NIH | 11/10/2026 | $0 |
| | 2027 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA293419 | Alternative splicing and isoform expression as mediators for the genetic etiology of breast cancer | 000 | 1 | NIH | 11/2/2026 | $0 |
| | 2027 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K23DA049216 | Multi-parametric MRI Assessment of Brain Connectivity and Spectroscopic Biomarkers in Patients with a Substance Use Disorder | 000 | 5 | NIH | 11/10/2026 | $0 |
| | 2027 | 2024 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251150 | Characterization and modeling of m6A RNA methylation in cancer | 000 | 5 | NIH | 10/13/2026 | -$1 |
| | 2027 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD013715 | A Randomized Controlled Trial of Mail-Self Stamped HPV Testing to Increase Cervical Cancer Screening Participation Among Minority/Underserved Women in an Integrated Safety Net Healthcare System | 000 | 6 | NIH | 11/5/2026 | $0 |
| | 2027 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P50CA221703 | The University of Texas MD Anderson Cancer Center SPORE in Melanoma | 001 | 5 | NIH | 10/28/2026 | $0 |
| | 2027 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL154512 | Neural Mechanisms of Calcineurin Inhibitor-Induced Hypertension | 000 | 4 | NIH | 11/9/2026 | -$688 |
| | 2027 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE028290 | Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac device | 000 | 5 | NIH | 11/6/2026 | -$19,160 |
| | 2027 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE028290 | Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac device | 000 | 5 | NIH | 11/6/2026 | -$6,251 |
| | 2027 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P50CA221703 | The University of Texas MD Anderson Cancer Center SPORE in Melanoma | 000 | 5 | NIH | 10/13/2026 | -$235,393 |
| | 2027 | 2023 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21DE033533 | Advanced genetic systems for Fusobacterium nucleatum in oral and extra-oral pathologies | 000 | 2 | NIH | 11/12/2026 | $0 |
|
 | Issue Date FY: 2026 ( Subtotal = $203,539,120 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA304638 | Ultrasound-guided cancer immunotherapy with targeted nanodroplets | 000 | 1 | NIH | 6/16/2026 | $421,685 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA101642 | Training of Academic Gynecologic Oncologists | 000 | 21 | NIH | 7/3/2026 | $567,034 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31AR087163 | Investigating the role of O-GlcNAc in silencing retrotransposons in the skin | 001 | 1 | NIH | 5/21/2026 | $0 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA293361 | Modulation of the tumor microenvironment by Fusobacterium nucleatum and co-infecting microbes in colorectal cancer | 000 | 1 | NIH | 4/2/2026 | $660,541 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31AR087163 | Investigating the role of O-GlcNAc in silencing retrotransposons in the skin | 000 | 1 | NIH | 5/14/2026 | $38,189 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299449 | Computational Approaches to Reconstruct the Evolutionary History of Cancer Metastases | 000 | 1 | NIH | 5/5/2026 | $688,073 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 5 | NIH | 2/24/2026 | $556,146 |
|